| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cancer statistics, 2009.
|
CA Cancer J Clin
|
2009
|
83.57
|
|
2
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
3
|
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
|
N Engl J Med
|
2004
|
49.02
|
|
4
|
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.
|
Nat Genet
|
2008
|
43.63
|
|
5
|
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
|
Science
|
2006
|
24.54
|
|
6
|
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
|
N Engl J Med
|
2004
|
18.93
|
|
7
|
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
|
J Clin Oncol
|
2008
|
15.17
|
|
8
|
Effector memory T cells, early metastasis, and survival in colorectal cancer.
|
N Engl J Med
|
2005
|
12.64
|
|
9
|
Circulating mutant DNA to assess tumor dynamics.
|
Nat Med
|
2007
|
10.33
|
|
10
|
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
J Clin Oncol
|
2010
|
10.17
|
|
11
|
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
|
Lancet
|
2008
|
9.92
|
|
12
|
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
|
J Clin Oncol
|
2011
|
8.66
|
|
13
|
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
|
Eur J Cancer
|
1999
|
8.29
|
|
14
|
Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.
|
Cancer
|
1996
|
7.38
|
|
15
|
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
|
Cancer
|
1994
|
6.31
|
|
16
|
Development of personalized tumor biomarkers using massively parallel sequencing.
|
Sci Transl Med
|
2010
|
6.08
|
|
17
|
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
|
J Clin Oncol
|
2005
|
6.00
|
|
18
|
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
|
J Clin Oncol
|
2011
|
5.63
|
|
19
|
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
|
Lancet Oncol
|
2009
|
5.57
|
|
20
|
Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.
|
Ann Surg
|
2008
|
4.86
|
|
21
|
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
|
Ann Oncol
|
2004
|
4.78
|
|
22
|
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
|
Cancer Immunol Immunother
|
2006
|
4.48
|
|
23
|
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
|
J Clin Oncol
|
2008
|
4.37
|
|
24
|
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
|
J Clin Oncol
|
2009
|
3.97
|
|
25
|
Immune infiltration in human tumors: a prognostic factor that should not be ignored.
|
Oncogene
|
2009
|
3.90
|
|
26
|
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
|
Clin Cancer Res
|
2009
|
3.41
|
|
27
|
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
|
Cancer Res
|
2001
|
3.32
|
|
28
|
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
3.09
|
|
29
|
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
|
Eur J Cancer
|
2012
|
2.79
|
|
30
|
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
|
J Clin Oncol
|
2008
|
2.52
|
|
31
|
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
|
Clin Cancer Res
|
2011
|
2.44
|
|
32
|
Coordination of intratumoral immune reaction and human colorectal cancer recurrence.
|
Cancer Res
|
2009
|
2.37
|
|
33
|
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.
|
Cancer Res
|
2007
|
2.34
|
|
34
|
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
|
Ann Oncol
|
2006
|
2.28
|
|
35
|
Hepatic resection for metastatic colorectal cancer results in cure for some patients.
|
Arch Surg
|
1997
|
2.13
|
|
36
|
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
|
Cancer
|
2007
|
2.12
|
|
37
|
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
|
Genes Chromosomes Cancer
|
2010
|
2.11
|
|
38
|
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.
|
Cancer Res
|
2011
|
2.08
|
|
39
|
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer.
|
Gastroenterology
|
2009
|
2.01
|
|
40
|
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
|
J Clin Oncol
|
2005
|
1.93
|
|
41
|
Immunogenic cancer cell death: a key-lock paradigm.
|
Curr Opin Immunol
|
2008
|
1.89
|
|
42
|
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
|
J Transl Med
|
2008
|
1.77
|
|
43
|
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).
|
Ann Surg
|
2005
|
1.72
|
|
44
|
Natural immunity to cancer in humans.
|
Curr Opin Immunol
|
2010
|
1.69
|
|
45
|
Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
|
Cancer
|
2002
|
1.60
|
|
46
|
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
|
Ann Surg Oncol
|
2010
|
1.32
|
|
47
|
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
|
J Transl Med
|
2009
|
1.31
|
|
48
|
TNM staging in colorectal cancer: T is for T cell and M is for memory.
|
J Clin Oncol
|
2011
|
1.30
|
|
49
|
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
|
Am J Surg Pathol
|
2010
|
1.22
|
|
50
|
Chronic myeloid leukemia: molecular monitoring in clinical practice.
|
Hematology Am Soc Hematol Educ Program
|
2007
|
1.19
|
|
51
|
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
|
J Am Coll Surg
|
2007
|
1.19
|
|
52
|
Modern multimodality approach to hepatic colorectal metastases: solutions and controversies.
|
Surg Oncol
|
2007
|
1.18
|
|
53
|
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
|
Eur J Surg Oncol
|
2009
|
1.13
|
|
54
|
Adjuvant therapy for stage II and III colorectal cancer.
|
Semin Oncol
|
2007
|
1.05
|
|
55
|
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
|
Ann Surg Oncol
|
2006
|
0.98
|
|
56
|
Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
|
J Surg Oncol
|
2012
|
0.87
|